Compare Vale SA (VALE) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vale SA vs Viatris Inc — how do they compare? Vale SA trades at $14.39 (market cap $61.97B), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Vale SA is far larger — about 3.3× Viatris Inc's market cap, and Vale SA pays the higher dividend (8.35%). Which is the better fit depends on your goals.
| VALE | VTRS | |
|---|---|---|
Market Cap | $61.97B | $18.69B |
Sector | Basic Materials | Health |
52-Week High | $17.82 | $17.86 |
52-Week Low | $9.71 | $9.49 |
Enterprise Value | $78.22B | $30.80B |
Dividend Yield | 8.35% | 2.95% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
